Should you invest in... the biotech business?

IF YOU are an investor looking for a "frontier market", you do not have to stray far from home. For those research-based companies at the cutting edge of technological development will give you a rollercoaster ride for your money every bit as exciting, and fraught with risk, as any emerging market.

Chief among these high- risk enterprises are the biotechnology stocks, those companies whose raison d'etre is to develop new products and processes through biochemical research and whose success or failure is often dependent upon their ability to develop and market a single new drug.

"There are very few biotech stocks that we look at, because the companies are so tiny and it has been an awful subsector to be in," says Jeremy Batstone of NatWest Stockbrokers. "It is an unloved sector which has seen a lot of disappointments, the most high profile of which was British Biotech."

In contrast to the outperformance of their bigger counterparts in the pharmaceutical companies, the small biotech sector has been suffering. Mark Mathias, marketing director of Finsbury Asset management,says: "Biotech shares have been complete dogs for two years. There have been some celebrated cases of bad management, which led to a bad press for the sector, which has depressed sentiment."

Glenn Meyer of Pavilion Asset Management says: "You have to adopt a portfolio approach to the biotech sector. Investing in individual biotech companies should be left to the specialists."

Lesley Buckett of Hill Samuel Asset Management says: "They are mainly very small cap stocks. The private investor would have to buy a lot of them to make an impact and the best way would be to have a portfolio via something like an investment trust. People who specialise in looking only at these stocks get it wrong, so what chance does the individual have? You are dealing with `blue sky' research, and how do you know that these scientists are actually going to come up with anything?"

Jeremy Batstone adds: "The trouble with biotech stocks is that they have had their glory days. Two or three years ago, when British Biotech's `wonder drug' was starting trials, these stocks were racing away and standing on ridiculous multiples. But as they have no earnings you can't properly rate companies like that - British Biotech was almost in the FTSE 100 at one point and hadn't actually produced anything. Now you can really see the wood for the trees and there isn't much of either."

Lesley Buckett says: "Biotech stocks were very lowly rated, then got very highly rated very quickly, as things like British Biotech began to take off. The pharmaceutical sector is a large part of the market, but that is on the basis of three very large stocks. The biotech companies have become even smaller with the derating they have experienced over the past couple of years."

Much of the problems associated with the sector have stemmed from long lead time. Mark Mathias says: "The underlying businesses take cash at the outset, then there is a long period when nothing seems to be happening because they are in the laboratory coming up with the drugs. So there was no news coming out of the biotechs, then bad news because of British Biotech and other bad management situations. Now positive news is coming through."

Jeremy Batstone says: "A company will build up market expectation of finding a cure for cancer or whatever, then let you down in a big way when you find it doesn't work. It means taking giant leaps of faith." Lesley Buckett says: "Ratings have become more sensible and you are beginning to see the same sort of cycle you see in the US. But these companies burn cash at an enormous rate. They will all need refinancing at some point."

When it does work, the rewards can be enormous and the best evidence comes from America. Mathias adds: "Biotech companies make profits by doing deals. There are 21 biotech companies in the US representing a total of $1.5bn (pounds 940m) in profits and this figures is going to rise to $2.5bn by the end of 2000. And they are available on an average p/e of 25 times earnings, which is reasonable.Some companies, like Powderject Pharmaceuticals, have developed world-leading technologies, although in this case it is a delivery system rather than an actual drug. SkyePharma is a company with successful technology, as is Chiroscience."

Jeremy Batstone says: "You have to consider how they are going to sell these drugs. Have they got marketing power? Chiroscience had a deal with Zeneca to market a drug, then after the Zeneca-Astra dealChiroscience was out in the cold, because Astra had a similar drug and didn't want a third party involved."

Voices
Scotland's First Minister Alex Salmond delivers his speech at the Scottish National Party (SNP) Spring Conference in Aberdeen, Scotland April 12, 2014.
voices
Arts & Entertainment
Jessica Pare as Megan Draper and Jon Hamm as the troubled, melancholy Don Draper
tvAnd six other questions we hope Mad Men series seven will answer
Life & Style
The new low cost smartphone of Motorola, 'Motorola Moto G', is displayed in Sao Paulo, Brazil on November 13, 2013. The smartphone, with dimensions 65.9mm W x 129.9mm H x 6.0 - 11.6mm D is equipped with a Qualcomm Snapdragon 400 with quad-core 1,2 GHz CPU, a 4.5-inch display and Android Operating System 4.3 and a suggested price of $ 179 USD.
techData assessing smartphones has revealed tens of millions of phones are at risk of being harvested
News
David Beckham is planning to build a stadium in Miami’s port for a new football team he will own
news... in his fight for a football stadium in Miami's port area
VIDEO
News
weird newsMan live-photographs cracking of mysterious locked box on Reddit
Sport
Oliver Giroud kisses the Arsenal badge after giving the Gunners the lead
sportArsenal 3 West Ham 1: Two goals from the German striker and one piece of brilliance from Giroud puts the Gunners back above Everton
News
Plans to decriminalise non-payment of television licence fees would cost the BBC £500m according to estimates drawn up within the Corporation
people
News
weird news
Arts & Entertainment
Seeing red: James Dean with Sal Mineo in 'Rebel without a Cause'
filmAs 'Rebel without a Cause' is re-released, Geoffrey Macnab reveals how its star James Dean perfected his moody act
News
Obesity surgery in rats has been found to change the way the body processes alcohol
news
Arts & Entertainment
Heads up: Andy Scott's The Kelpies in Falkirk
artThe Kelpies are the latest addition to a growing army of giant sculptures. But naysayers are asking what a pair of gigantic horse heads tells us about Falkirk?
Life & Style
US Airways has been at the centre of a Twitter storm after it responded to customer complaints with a graphic sexual image
techUS Airways takes an interesting approach to customer service
Arts & Entertainment
Philip Arditti as Yossarian and Christopher Price as Milo Minderbinder in Northern Stage's 'Catch-22'
theatre
Arts & Entertainment
The Purple Wedding: Joffrey and Margaery Tyrell tie the knot
TV The second episode of the hit series featured a surprise for viewers
Life & Style
Back to nature: women with body issues have found naked yoga sessions therapeutic
lifeDoing poses in the altogether is already big in the US, and now it’s landed here – in mixed classes
Have you tried new the Independent Digital Edition iPad app?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Management Consultancy - Operational Research Analysts

£35000 - £50000 per annum + Bonus + Benefits: Pro-Recruitment Group: You must ...

Corporate Actions Consultant - Market data, ISO15022, presales

£45000 - £60000 per annum + BONUS + BENEFITS: Harrington Starr: Corporate Acti...

Prudential Risk/Operational Risk Associate - London

£350 - £400 per day: Harrington Starr: An opportunity has arisen at a FCA regu...

PhD/MSc educated Operational Research Analysts - Consultancy!

£35000 - £50000 per annum + Bonus + Benefits: Pro-Recruitment Group: You must ...

Day In a Page

Homelessness: Why is the supported lodgings lifeline under threat?

Why is the supported lodgings lifeline under threat?

Zubairi Sentongo swapped poverty in Uganda for homelessness in Britain. But a YMCA scheme connected him with a couple offering warmth and shelter
A History of the First World War in 100 Moments: When the world’s biggest shed took over Regent’s Park

A History of the First World War in 100 Moments

When the world’s biggest shed took over Regent’s Park
The pain of IVF

The pain of IVF

As an Italian woman vows to keep the babies from someone else’s eggs, Julian Baggini ponders how the reality of childbirth is often messier than the natural ideal
Supersize art

Is big better? Britain's latest super-sized art

The Kelpies are the latest addition to a growing army of giant sculptures. But naysayers are asking what a pair of gigantic horse heads tells us about Falkirk?
James Dean: Back on the big screen

James Dean: Back on the big screen

As 'Rebel without a Cause' is re-released, Geoffrey Macnab reveals how its star perfected his moody act
Catch-22: How the cult classic was adapted for the stage

How a cult classic was adapted for the stage

More than half a century after it was published 'Catch-22' will make its British stage debut next week
10 best activity books for children

10 best activity books for children

Keep little ones busy this bank holiday with one of these creative, educational and fun books
Arsenal 3 West Ham United 1: Five things we learnt from the battle between the London sides

Five things we learnt from Arsenal's win over West Ham

Arsenal still in driving seat for Champions League spot and Carroll can make late charge into England’s World Cup squad
Copa del Rey final: Barcelona are paying for their complacency and not even victory over Real Madrid will put things right

Pete Jenson on the Copa del Rey final

Barcelona are paying for their complacency and not even victory over Real Madrid will put things right
Rafa to reign? Ten issues clay courts will serve up this season

Rafa to reign? Ten issues clay courts will serve up this season

With the tennis circus now rolling on to the slowest surface, Paul Newman highlights who'll be making the headlines – and why
Exclusive: NHS faces financial disaster in 2015 as politicians urged to find radical solution

NHS faces financial disaster in 2015

Politicians urged to find radical solution
Ukraine crisis: How spontaneous are the pro-Russian protests breaking out in Ukraine’s east?

Ukraine crisis

How spontaneous are the pro-Russian protests breaking out in Ukraine’s east?
A History of the First World War in 100 moments: The first execution at the Tower of London for 167 years

The first execution at the Tower of London for 167 years

A history of the First World War in 100 moments
Fires could turn Amazon rainforest into a desert as human activity and climate change threaten ‘lungs of the world’, says study

New threat to the Amazon rainforest:

Fires that scorch the ‘lungs of the Earth’
Liverpool, Chelsea and Manchester City: And the winner of this season’s Premier League title will be...

Who’s in box seat now? The winner of the title will be ...

Who is in best shape to take the Premier League prize?